EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Metabolomics and Lipidomics for Studying Metabolic Syndrome: Insights into Cardiovascular Diseases, Type 1 & 2 Diabetes, and Metabolic Dysfunction-Associated Steatotic Liver Disease

S Rakusanova, T Cajka

Physiological Research · 31.08.2024 · (Suppl 1) · S165-S183

DOI: 10.33549/physiolres.935443 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Physiological Research, erschienen am 31.08.2024. Verfasst von S Rakusanova und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Translational Metabolism, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic. tomas.cajka@fgu.cas.cz. Hauptthemen laut MEDLINE: Metabolic Syndrome, Metabolomics, Lipidomics, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolomics and lipidomics have emerged as tools in understanding the connections of metabolic syndrome (MetS) with cardiovascular diseases (CVD), type 1 and type 2 diabetes (T1D, T2D), and metabolic dysfunction-associated steatotic liver disease (MASLD). This review highlights the applications of these omics approaches in large-scale cohort studies, emphasizing their role in biomarker discovery and disease prediction. Integrating metabolomics and lipidomics has significantly advanced our understanding of MetS pathology by identifying unique metabolic signatures associated with disease progression. However, challenges such as standardizing analytical workflows, data interpretation, and biomarker validation remain critical for translating research findings into clinical practice. Future research should focus on optimizing these methodologies to enhance their clinical utility and address the global burden of MetS-related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeMetabolomicsLipidomicsDiabetes Mellitus, Type 2Cardiovascular DiseasesHumansDiabetes Mellitus, Type 1AnimalsBiomarkersFatty Liver

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Laboratory of Translational Metabolism, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic. tomas.cajka@fgu.cas.cz.

Zitieren

APA

Rakusanova, S., & Cajka, T. (2024). Metabolomics and Lipidomics for Studying Metabolic Syndrome: Insights into Cardiovascular Diseases, Type 1 & 2 Diabetes, and Metabolic Dysfunction-Associated Steatotic Liver Disease. Physiological Research, S165-S183. https://doi.org/10.33549/physiolres.935443

Vancouver

Rakusanova S, Cajka T. Metabolomics and Lipidomics for Studying Metabolic Syndrome: Insights into Cardiovascular Diseases, Type 1 & 2 Diabetes, and Metabolic Dysfunction-Associated Steatotic Liver Disease. Physiological Research. 2024:S165-S183. doi:10.33549/physiolres.935443

BibTeX
@article{Rakusanova2024,
  author = {Rakusanova, S and Cajka, T},
  title = {Metabolomics and Lipidomics for Studying Metabolic Syndrome: Insights into Cardiovascular Diseases, Type 1 & 2 Diabetes, and Metabolic Dysfunction-Associated Steatotic Liver Disease},
  journal = {Physiological Research},
  year = {2024},
  number = {Suppl 1},
  pages = {S165--S183},
  doi = {10.33549/physiolres.935443}
}
Kostenlos starten →